Pfizer and Valneva's Lyme Disease Vaccine Shows 73% Efficacy in Phase 3 Trial

Event summary

  • Pfizer and Valneva's Lyme disease vaccine candidate PF-07307405 demonstrated 73.2% efficacy in reducing confirmed Lyme disease cases in Phase 3 VALOR trial.
  • The primary endpoint's statistical criterion was not met due to fewer Lyme disease cases than anticipated, but the secondary endpoint showed a 74.8% efficacy.
  • The vaccine targets six Borrelia OspA serotypes prevalent in North America and Europe.
  • Pfizer plans to submit the data to regulatory authorities despite the primary endpoint miss.

The big picture

Pfizer and Valneva's Lyme disease vaccine represents a significant step forward in addressing a growing public health concern, with Lyme disease cases rising in both the U.S. and Europe. The vaccine's efficacy data, though mixed, highlights the potential to fill a critical gap in preventive care for a disease with no current approved vaccine. The strategic collaboration between Pfizer and Valneva underscores the importance of partnerships in accelerating vaccine development for unmet medical needs.

What we're watching

Regulatory Pathway
Whether regulatory authorities will accept the secondary endpoint data for approval given the primary endpoint miss.
Market Potential
The pace at which Pfizer can commercialize the vaccine if approved, given the growing incidence of Lyme disease.
Competitive Landscape
How this development positions Pfizer and Valneva against potential future competitors in the Lyme disease vaccine space.

Related topics

Public Health